Comparison of Adverse-Event Profiles of Intravenous Low-Molecular-Weight Iron Dextran and Iron Sucrose in Peritoneal Dialysis Patients

Figures & data

Table 1. Laboratory data of chronic peritoneal dialysis patients administered LMW-ID and iron sucrose

	Total (n = 167)	LMW-ID (n = 92)	Iron sucrose (n = 75)	p-Value
Age (years)	53.2 ± 15.6	55.6 ± 14.4	50.1 ± 16.6	NS
Gender (F/M)	91/76	49/43	42/33	NS
Serum iron (mg/dL)	35.5 ± 26.8	34.5 ± 28.6	37.1 ± 23.8	NS
Total iron-binding capacity (µg/dL)	186.8 ± 75.2	192.0 ± 82.9	178.8 ± 61.6	NS
Ferritin (ng/mL)	289.5 ± 243.4	250.7 ± 193.5	348.9 ± 296.7	0.029
Hemoglobin (g/dL)	9.7 ± 1.4	9.6 ± 1.4	9.8 ± 1.3	NS
C-reactive protein (mg/dL)	32.3 ± 33.5	30.4 ± 32.6	35.7 ± 35.2	NS
PTH (pg/dL)	321.7 ± 249.2	323.9 ± 255.4	319.2 ± 244.4	NS
Urea (mg/dL)	127.9 ± 49.3	124.2 ± 47.7	134.2 ± 51.6	NS
Creatinine (mg/dL)	5.8 ± 2.9	5.1 ± 2.6	7.2 ± 3.0	<0.001

Note: LMW-ID, low-molecular-weight iron dextran; PTH, parathormone; NS, not significant.

Figure 1. Diagram showing the type and amount of parenteral iron solution administered to chronic peritoneal dialysis patients.